Cutaneous Melanoma Clinical Trial
Official title:
Imaging Modalities for Melanoma Screening and Diagnosis
This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
PRIMARY OBJECTIVE: I. To assess the clinical utility of clinical images, digital dermoscopy images and in-vivo confocal microscopy for teledermatology. SECONDARY OBJECTIVE: I. To incorporate in vivo confocal images into the triage system in order to determine to what degree the information gathered in this modality changes the classification of a lesion assigned by a licensed dermatologist. TERTIARY OBJECTIVE: I. To assess the potential improvement of virtual patient triage when adding digital dermoscopy images to clinical images presented by patients to their provider (via e-visit or e-consult). OUTLINE: Participants undergo imaging of suspicious moles via smartphone application (app) MoleMapper/Sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. Participants then receive lidocaine subcutaneously (SC) and undergo shave or punch biopsy of suspected melanomas. After completion of study intervention, patients are followed up within 1 week. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04020809 -
Neoadjuvant Atezolizumab in Cutaneous Melanoma
|
Phase 1 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Completed |
NCT03628417 -
Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases
|
N/A | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
Recruiting |
NCT05253872 -
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
|
N/A | |
Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04792463 -
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
|
||
Completed |
NCT00679289 -
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
Recruiting |
NCT04702854 -
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
|
N/A |